Study Name:
EFC15858

Targeted Disease(s):
Lung Cancer

Purpose of Study:

Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors

Study Dates:
February 6, 2020 - April 10, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
Sarah Cannon Research Institute

Funding Source:
Sanofi

Sponsors:

Sanofi

ClinicalTrails.gov Identifier:
NCT04154956

Register for Trial
Asthma Basics Workshop - National
, | Feb 21, 2024
Asthma Basics Workshop - National
, | Mar 20, 2024